干细胞移植治疗骨髓增生异常综合征13例

 目的　探讨干细胞移植（HSCT）在骨髓增生异常综合征（MDS）治疗中的疗效以及预处理方式的选择。方法　对13例MDS患者行异基因造血干细胞移植 （allo-HSCT）（包括HLA配型全相合10例、半相合2例、脐血移植1例）。输注单个核细胞（MNC） 6.92（2.65～21.33）×108／kg，CD34细胞4.47（1.49～10.22）×106／kg。其中，5例选择全身照射+氟达拉滨+环磷酰胺（TBI+Flud+Cy）方案预处理，3例白消安（BU）／Cy预处理，3例TBI+CY，2例采用阿糖胞苷（Ara-C）+BU+Cy+替尼泊苷（VM26）预处理。移植物抗宿主病（GVHD）的预防：2例HLA配型半相合者给予抗胸腺细胞球蛋白（ATG）联合环孢素A（CsA）加短程甲氨蝶呤（MTX）治疗，并于移植后1～28 d持续给予霉酚酸酯（MMF），其他病例仅给予CsA加短程MTX。结果　13例患者中9例造血完全重建，移植相关死亡4例。结论　HSCT是可以治愈MDS的有效方法。预处理选择应采取个体化。

The effect of hematopoietic stem cell transplantation on myelodysplastic syndrome

Objective To investigate the curative effect of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and the method of the pretreatment choice on myelodysplastic syndrome (MDS).Methods 13 cases who were undergoing allo-HSCT including 10 HLA-matched, 2 HLA partially matched,and one umbilical cord blood transplanted patients were enrolled in this study. The infusion number of MNC and CD+34 cells is 6.92 (2.65-21.33)×108/kg and 4.47 (1.49-10.22) ×106/kg, respectively. Of the 13 cases,5 adopted TBI, fludarabine(Flud), and cyclophosphamide(Cy) pretreatment, 3 chose BU/Cy pretreatment, and 3 chose TBI and Cy pretreatment, 2 chose Ara-C+BU+Cy+VM26 pretreatment. In order to prevent GVHD, 2cases of HLA partially matched were treated with ATG, cyclosporin A (CsA), MTX and MMF aftertransplantation, while the others were treated with CsA and MTX only. Results 9 out of 13 cases achieved hematopoietic reconstruction completely. 4 died of complications. Conclusion The allogeneic hematopoietic stem cell transplantation is an efficient regimen to cure MDS. The pretreatment should adopt the individuation.